Clearly Indicated, Genuinely Unaffordable: A PCSK9 Inhibitor Against a High-Deductible Plan
Every guideline box checked for a PCSK9 inhibitor — established ASCVD, maximal statin plus ezetimibe, LDL still above threshold — against a health plan whose structure quietly excludes the usual affordability fix. The clinical decision was never really the hard part.
B.T., a 56-year-old man, has worked as a freelance graphic designer for over twenty years, building his own client base after leaving a design firm he'd outgrown — steady work, but the kind that comes with a marketplace health plan he shops for himself every open enrollment. He had an anterior MI eighteen months ago, treated with a drug-eluting stent, and has been on atorvastatin 80mg plus ezetimibe 10mg since — maximally tolerated statin therapy, no myalgia, LFTs and CK normal throughout. Today's LDL is 95 mg/dL, well above the under-70 threshold that applies to him as a very-high-risk secondary-prevention patient. He meets the guideline criteria for a PCSK9 inhibitor cleanly — there is no clinical ambiguity here at all. What complicates today's visit is his coverage: a high-deductible marketplace plan with a $6,500 deductible, and self-employment income that varies enough year to year that he genuinely doesn't know whether he'd qualify for income-based assistance without checking.
PCSK9 inhibitors carry real, well-documented access friction independent of clinical appropriateness. Historical denial rates on first submission have run high, though thorough upfront documentation — confirmed ASCVD, a documented statin-plus-ezetimibe trial, current LDL above threshold — followed by a peer-to-peer review when needed now succeeds considerably more often than not. Manufacturer copay cards can bring a commercially insured patient's out-of-pocket cost down sharply, but these programs commonly exclude high-deductible, HSA-linked plans specifically from counting the assistance toward the deductible — exactly B.T.'s plan type. Separately, income-based patient assistance programs exist for patients with inadequate coverage whose household income falls below a program-specific ceiling — commonly somewhere in the 400% to 500% federal-poverty-level range, and revised year to year — a threshold his fluctuating self-employment income sits close enough to that it needs to actually be checked, not assumed either way.
Preventive cardiology, lipid follow-up
His clinical case is about as clean as this ever gets — confirmed ASCVD, a real statin-plus-ezetimibe trial, LDL above threshold. I'd submit a thorough prior authorization today with full documentation, and go straight to peer-to-peer review if it's initially denied — that combination succeeds well more often than not now.
The clinical approval question and the affordability question are genuinely separate — I'm confident about the first, less sure about the second.
Even if the PA clears, the usual fix might not apply to him. Manufacturer copay cards commonly exclude high-deductible, HSA-linked plans from counting toward the deductible — that's his exact plan type, not a generic caveat. And the income-based assistance program has a real threshold his self-employment income sits close enough to that we need to actually check it, not assume he qualifies or doesn't.
I'm not saying the drug is unreachable for him — I'm saying "there's a copay card" isn't actually an answer until someone confirms it applies to his coverage specifically.
While all of that gets sorted out — and it could take weeks — I'd start bempedoic acid today rather than leave his LDL unmanaged in the meantime. It's a real, guideline-listed option, not a placeholder, though I want to be honest that it carries its own real payer-rejection and out-of-pocket friction too — not a clean fallback, just a better position than doing nothing while we wait.
Agreed: start bempedoic acid today, submit the PCSK9 inhibitor prior authorization with complete documentation, and begin verifying both the copay-card applicability to his high-deductible plan and his patient-assistance-program eligibility in parallel rather than sequentially.
Not agreed, and carried forward explicitly rather than smoothed over:
All three voices agreed it becomes the primary non-statin therapy, with bempedoic acid either stopped or continued as an add-on depending on the LDL response at that point.
The Clinical Pharmacologist's caution is reinforced — bempedoic acid would likely remain his practical long-term therapy, not a bridge, and that outcome would need to be named honestly rather than treated as a temporary failure to fix later.
The Preventive Cardiologist's confidence in the clinical approval case was not in dispute — what remained genuinely unresolved by the end of the visit was whether approval would translate into a drug B.T. could actually afford to take.